Skip to content

Study · Animal study (in vivo) · mouse · 2009

5 results

Intraperitoneal co-administration of thymosin alpha-1 ameliorates streptozotocin-induced pancreatic lesions and diabetes in C57BL/6 mice.

Qiu L, Zhang C, Zhang J, Liang J, Liu J, Ji C, Yang JY

International journal of molecular medicine1 May 2009Cited by 7 (Europe PMC)

PMID19360317 (opens in a new tab)DOI10.3892/ijmm_00000169 (opens in a new tab)PepBankPUB-19360317
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In STZ-treated mice, thymosin alpha‑1 at both doses gave lower blood glucose than in STZ-treated mice without it, but glucose stayed higher than in normoglycemic controls.

    In plain wordsIn mice with STZ-induced diabetes, thymosin alpha‑1 lowered blood glucose compared with no treatment, but not to normal levels.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseBlood glucose
    Study

    mousen: not reported in source

    STZ-induced diabetes in C57BL/6 mice
    Comparator
    STZ-treated mice without Talpha-1
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.1 and 1 microg/kg/day · intraperitoneal · 35 daysAs given in this study (mouse).

    Source sentences

    Summary
    Fourteen days after the initiation of Talpha-1 treatment and up to day 35 when the treatment was stopped, both of the two STZ and Talpha-1-co-treated mouse groups had significant lower levels of blood glucose than the STZ-treated but Talpha-1-untreated mice, although both remained higher than that o…
    1 context sentence
    Summary · context
    Mice were randomly divided into four experimental groups: normoglycemic control, STZ-treated, STZ plus 0.1 microg/kg body weight/day Talpha-1-treated, and STZ plus 1 microg/kg/day Talpha-1-treated.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In STZ-treated mice, thymosin alpha‑1 at 1 microg/kg/day for 35 days raised serum insulin 2-fold (P<0.001) compared with untreated STZ-diabetic mice, without full restoration to the normal level.

    In plain wordsIn mice with STZ-induced diabetes, thymosin alpha‑1 raised blood insulin to twice the level of untreated diabetic mice, but not to normal.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSerum insulin
    Study

    mousen: not reported in source

    STZ-induced diabetes in C57BL/6 mice
    Comparator
    STZ-treated mice without Talpha-1
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1 microg/kg/day · intraperitoneal · 35 daysAs given in this study (mouse).

    Measurements

    Serum insulin fold change vs untreated STZ mice
    2 fold
    1 microg/kg/day

    Source sentences

    Summary
    At the end of the Talpha-1 treatment, the serum insulin level for STZ-treated mice receiving 1 microg/kg/day Talpha-1 for 35 days was 2-fold (P<0.001) as much as that of the Talpha-1-untreated STZ-diabetic mice, although not completely restored to the normal level.
    1 context sentence
    Summary · context
    Mice were randomly divided into four experimental groups: normoglycemic control, STZ-treated, STZ plus 0.1 microg/kg body weight/day Talpha-1-treated, and STZ plus 1 microg/kg/day Talpha-1-treated.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In STZ-treated mice, thymosin alpha‑1 at 1 microg/kg/day for 35 days significantly alleviated STZ-induced pancreatitis, islet atrophy and loss of pancreatic beta cells.

    In plain wordsIn mice with STZ-induced diabetes, thymosin alpha‑1 reduced damage to the pancreas and its insulin-making cells.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasePancreatic histological lesions (pancreatitis, islet atrophy, beta cell loss)
    Study

    mousen: not reported in source

    STZ-induced diabetes in C57BL/6 mice
    Comparator
    STZ-treated mice without Talpha-1
    Outcome group
    Islet protection · Endocrine and hormones
    Studied dose
    1 microg/kg/day · intraperitoneal · 35 daysAs given in this study (mouse).

    Source sentences

    Summary
    Pancreatic aldehyde fuchsin staining showed that STZ treatment caused significant pancreatitis, islet atrophy, and a significant reduction in the number of pancreatic beta cells. These histological lesions, however, were significantly alleviated by 1 microg/kg/day Talpha-1 treatment for 35 days.
    1 context sentence
    Summary · context
    Mice were randomly divided into four experimental groups: normoglycemic control, STZ-treated, STZ plus 0.1 microg/kg body weight/day Talpha-1-treated, and STZ plus 1 microg/kg/day Talpha-1-treated.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In STZ-treated mice, thymosin alpha‑1 at 1 microg/kg/day raised pancreatic GSH to 1.92-fold that of untreated STZ-induced mice (P<0.01).

    In plain wordsIn mice with STZ-induced diabetes, thymosin alpha‑1 raised the antioxidant glutathione in the pancreas compared with untreated diabetic mice.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePancreatic GSH level
    Study

    mousen: not reported in source

    STZ-induced diabetes in C57BL/6 mice
    Comparator
    STZ-treated mice without Talpha-1
    Outcome group
    Oxidative stress · Endocrine and hormones
    Studied dose
    1 microg/kg/day · intraperitoneal · 35 daysAs given in this study (mouse).

    Measurements

    Pancreatic GSH fold change vs untreated STZ mice
    1.92 fold
    1 microg/kg/day

    Source sentences

    Summary
    the pancreatic GSH level of the 1 microg/kg/day Talpha-1-treated STZ-induced mice was 1.92-fold that of the untreated STZ-induced mice (P<0.01)
    1 context sentence
    Summary · context
    Mice were randomly divided into four experimental groups: normoglycemic control, STZ-treated, STZ plus 0.1 microg/kg body weight/day Talpha-1-treated, and STZ plus 1 microg/kg/day Talpha-1-treated.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In STZ-treated mice, thymosin alpha‑1 at 1 microg/kg/day lowered pancreatic MDA to 81.9% of the level in untreated STZ-diabetic mice (P<0.05).

    In plain wordsIn mice with STZ-induced diabetes, thymosin alpha‑1 lowered a marker of oxidative damage in the pancreas compared with untreated diabetic mice.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasePancreatic MDA level
    Study

    mousen: not reported in source

    STZ-induced diabetes in C57BL/6 mice
    Comparator
    STZ-treated mice without Talpha-1
    Outcome group
    Oxidative stress · Endocrine and hormones
    Studied dose
    1 microg/kg/day · intraperitoneal · 35 daysAs given in this study (mouse).

    Measurements

    Pancreatic MDA relative to untreated STZ mice
    81.9%
    1 microg/kg/day

    Source sentences

    Summary
    whereas the pancreatic MDA level was only 81.9% that of the untreated STZ-diabetic mice (P<0.05)
    1 context sentence
    Summary · context
    Mice were randomly divided into four experimental groups: normoglycemic control, STZ-treated, STZ plus 0.1 microg/kg body weight/day Talpha-1-treated, and STZ plus 1 microg/kg/day Talpha-1-treated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.